Impact of implementing a vancomycin protocol to reduce kidney toxicity: A comparative study.

Area of Science:

• Pharmacology and Therapeutics
• Nephrology
• Infectious Diseases

Background:

• Vancomycin is critical for treating Gram-positive infections but carries nephrotoxicity risks.
• Effective vancomycin use requires careful administration and dose monitoring to balance efficacy and safety.
• Understanding vancomycin's impact on clinical outcomes, including acute kidney injury (AKI), is essential.

Purpose of the Study:

• To evaluate the incidence of AKI in patients receiving vancomycin before and after implementing an institutional protocol.
• To assess the impact of a standardized vancomycin administration protocol on patient safety and clinical outcomes.

Main Methods:

• A cross-sectional study analyzed electronic medical records of 422 patients receiving vancomycin.
• Patients were divided into two cohorts: 2016 (pre-protocol) and 2018 (post-protocol).
• Logistic regression and ROC curve analysis were used to predict AKI and assess model performance (AUC 0.764).

Main Results:

• The post-protocol cohort (2018) showed a significant reduction in AKI incidence (20.9%) compared to the pre-protocol cohort (38.4%) (p < 0.001).
• Post-protocol patients were older and had higher baseline creatinine, increased ICU admissions, and vasopressor use.
• The logistic regression model demonstrated acceptable discrimination for predicting AKI.

Conclusions:

• Implementation of the institutional vancomycin administration protocol significantly reduced AKI incidence.
• The protocol ensured appropriate therapeutic dosing, leading to fewer adverse events like nephrotoxicity.
• The protocol demonstrated a significant, cost-effective impact on improving patient clinical outcomes.